Payment overview · 2025
General Payments
$1,238.34
28 reported records · 7 companies
Healthcare provider profile · identity verified
Mark W. Li, M.D.
Allopathic & Osteopathic Physicians|General Practice · HACIENDA HTS, CA · NPI 1356375059
Verified facts
What the public records show
CMS Open Payments records show Mark W. Li, M.D. received $1,238.34 in general payments during 2025 across 28 reported records.
Gilead Sciences, Inc. accounted for 44.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vemlidy.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vemlidy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $554.05 | 44.7% | 18 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $177.56 | 14.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $175.00 | 14.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $159.80 | 12.9% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $125.00 | 10.1% | 1 | 2025 |
| Intercept Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.75 | 1.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $23.18 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,043.35 | 26 |
| Consulting Fee | $175.00 | 1 |
| Education | $19.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $177.56 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $175.00 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $159.80 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Vemlidy Normalized: vemlidy |
Drug | Gilead Sciences, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| OCALIVA Normalized: ocaliva |
Drug | Intercept Pharmaceuticals, Inc. | $23.75 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $23.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Vemlidy vemlidy |
2025 | Vemlidy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 603 | 298 |
| Sucralfate | Sucralfate | 359 | 177 |
| Sod Sulf-Potass Sulf-Mag Sulf | Sodium, Potassium,mag Sulfates | 248 | 246 |
| Amlodipine Besylate | Amlodipine Besylate | 209 | 33 |
| Atorvastatin Calcium | Atorvastatin Calcium | 155 | 31 |
| Levetiracetam | Levetiracetam | 152 | 15 |
| Levothyroxine Sodium | Levothyroxine Sodium | 145 | 24 |
| Famotidine | Famotidine | 120 | 44 |
| Alendronate Sodium | Alendronate Sodium | 99 | 13 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 90 | 11 |
| Losartan Potassium | Losartan Potassium | 88 | 20 |
| Risperidone | Risperidone | 82 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 63 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 58 | suppressed |
| Carbamazepine Er | Carbamazepine | 56 | suppressed |
| Meloxicam | Meloxicam | 56 | 15 |
| Benztropine Mesylate | Benztropine Mesylate | 50 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | suppressed |
| Eliquis | Apixaban | 48 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 48 | suppressed |
| Metformin Hcl | Metformin Hcl | 48 | suppressed |
| Sodium Chloride | Sodium Chloride Irrig Solution | 46 | suppressed |
| Gavilyte-G | Peg3350/Sod Sulf,bicarb,cl/Kcl | 45 | 45 |
| Carvedilol | Carvedilol | 44 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 43 | suppressed |
| Potassium Chloride | Potassium Chloride | 41 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 41 | suppressed |
| Carbamazepine | Carbamazepine | 40 | suppressed |
| Lacosamide | Lacosamide | 40 | suppressed |
| Hydrocortisone | Hydrocortisone | 39 | 18 |
| Megestrol Acetate | Megestrol Acetate | 36 | suppressed |
| Vascepa | Icosapent Ethyl | 36 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 34 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 29 |
| Budesonide | Budesonide | 31 | suppressed |
| Simvastatin | Simvastatin | 31 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Enulose | Lactulose | 29 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 28 | suppressed |
| Gabapentin | Gabapentin | 27 | suppressed |
| Livalo | Pitavastatin Calcium | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 26 | suppressed |
| Lorazepam | Lorazepam | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Lisinopril | Lisinopril | 24 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 24 | suppressed |
| Clarithromycin | Clarithromycin | 23 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 22 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Scopolamine | Scopolamine | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Furosemide | Furosemide | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Sulfasalazine | Sulfasalazine | 16 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Phenytoin | Phenytoin | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Clobazam | Clobazam | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,238.34 · 28 records | Gilead Sciences, Inc. | BREZTRI, OCALIVA, PROLIA, VOQUEZNA, Vemlidy, Wegovy, ZORYVE | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vemlidy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Gilead Sciences, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error